HONG KONG, Sept. 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug...
Hence then, the article about akeso s egfr trop2 bispecific adc ak158d1 granted nmpa phase i clearance for advanced solid tumors marking its fourth clinical stage adc candidate was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate )
Also on site :
- Walmart’s $18 Pearl Drop Earrings With Swarovski Crystals Are a Quiet-Luxury Staple That ‘Look Very Expensive’
- Bran Flakezz on Winning ‘Unwell Summer Games,’ His Future With Reality TV and the Alex Cooper-Alix Earle Drama
- If Someone Uses This ‘Firehose Strategy’ on You in an Argument, a Psychologist Says It’s High-Level Gaslighting